Preliminary Reliability and Validity Testing of a New Skin Toxicity Assessment Tool (STAT) in Breast Cancer Patients Undergoing Radiotherapy
- 1 December 2004
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 27 (6) , 626-631
- https://doi.org/10.1097/01.coc.0000138965.97476.0f
Abstract
Clear consensus on the clinical evaluation of acute skin toxicity among cancer patients undergoing radical radiotherapy (RT) is currently lacking. This study investigates the reliability and validity of a new Skin Toxicity Assessment Tool (STAT) to evaluate the objective and subjective manifestations of RT-induced acute skin effects. The STAT was designed by a multidisciplinary team involved in the management of radiation skin reactions. The tool has 3 components: patient and treatment parameters, observer scoring, and patient-reported symptoms, and was piloted in a cohort of 27 breast cancer patients by pairs of independent blinded observers. Each patient was assessed weekly during RT and 2 weeks after therapy completion. Validity and reliability testing of the STAT was performed. Information on the tool's ease of use was obtained by recording the time necessary to complete the assessment at each visit and by a survey among the tool's users. All subjects developed some degree of skin reaction during breast RT. The level of agreement between observers in eliciting subjective complaints ranged from 72% to 92% (95% CI = 63–96%; κ = 0.33–0.68). The interobserver agreement in scoring skin reactions ranged from 65.0 to 97.5% (κ = 0.46–0.81). Objective and subjective toxicity scores were significantly correlated (P < 0.05). The STAT was easy to use and required on average a few minutes to complete at each visit. The STAT is an easy-to-use, standardized instrument to evaluate acute skin reaction and may be applied to clinical care and research in patients undergoing radiotherapy.Keywords
This publication has 22 references indexed in Scilit:
- Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind studyBritish Journal of Dermatology, 2002
- Phase II study assessing the effectiveness of Biafine cream as a prophylactic agent for radiation-induced acute skin toxicity to the breast in women undergoing radiotherapy with concomitant CMF chemotherapyPublished by Elsevier ,2001
- Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized studyPublished by Elsevier ,2001
- Randomized phase III study comparing best supportive care to biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation therapy oncology group (RTOG) 97-13International Journal of Radiation Oncology*Biology*Physics, 2000
- Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicityInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Skin Treatment with Bepanthen Cream Versus No Cream During Radiotherapy: A randomized controlled trialActa Oncologica, 1996
- Pathophysiology of irradiated skin and breastInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology*Biology*Physics, 1995
- The Skin: Its Structure and Response to Ionizing RadiationInternational Journal of Radiation Biology, 1990
- Complications of radiation therapy and factors in their preventionWorld Journal of Surgery, 1986